Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | STAT1 | P42224 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17449164 | 0.81 | LPL (0.32) | LPLLIPG | |
| SCHEMBL17449002 | 0.80 | PRKCA (0.34) | PRKCANFKB1STAT1NFKB2RELA | |
| SCHEMBL17449162 | 0.76 | NFKB1 (0.32) | PRKCANFKB1STAT1NFKB2RELA | |
| SCHEMBL16094973 | 0.74 | PSEN1 (0.34) | LPLLIPGPRKCA | |
| SCHEMBL16118390 | 0.70 | — | — | |
| SCHEMBL16118389 | 0.69 | PRKCA (0.35) | PRKCANFKB1STAT1NFKB2RELA | |
| SCHEMBL3655929 | 0.67 | P2RX7 (0.47) | LPLLIPG | |
| SCHEMBL17449017 | 0.66 | PKM (0.38) | — | |
| SCHEMBL17449005 | 0.64 | MIF (0.33) | PRKCA | |
| SCHEMBL17449161 | 0.64 | NFKB1 (0.31) | PRKCANFKB1STAT1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158678-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014151258-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016942-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885PRKCA 152/4885 |
| US-20170158678-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS | FLT3, ABL1, FES | LPL 3781/4885LIPG 1966/4885PRKCA 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.